Component

Insulin secretion

Independent cellular process record for Insulin secretion.

7 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. The human recall-by-genotype study found greater insulin-secretion reduction and glucose elevation in G-allele carriers.

    Melatonin → Insulin secretion source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/melatonin-research/27185156.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "61fcf7c730c1349e5b306e5c9cfcabcb2905290d7f8762cbfba06f2b5fccaded", "start_char": 0, "end_char": 1043, "text_sha256": "61fcf7c730c1349e5b306e5c9cfcabcb2905290d7f8762cbfba06f2b5fccaded"}
    experimental_model
    Human islet genetics, cell experiments and recall-by-genotype intervention
    exposure
    Risk G allele, receptor overexpression and melatonin exposure
    limitations
    Genotype associations, cultured-cell manipulation and human intervention are separate evidence types. Do not generalize islet signaling to every tissue.
    nutrient_topic
    Melatonin research collection; topical membership is not evidence of a direct dietary effect. · Melatonin
    organism
    Human islets and volunteers; separate insulin-cell and mouse experiments
    plain_language
    A response can vary with receptor genotype.
    primary_references
    [melatonin-p27185156] Increased Melatonin Signaling Is a Risk Factor for Type 2 Diabetes. (2016). https://pubmed.ncbi.nlm.nih.gov/27185156/ DOI: 10.1016/j.cmet.2016.04.009
    tissue_or_cell_type
    MTNR1B signaling and insulin secretion

    Melatonin: synthesis, receptors, circadian timing and nutrient interactions (2026-09-17) · lines 1137–1148

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Human islet genetics, cell experiments and recall-by-genotype intervention · source_derived_draft · unverified_draft

    ### melatonin-genotype-human-insulin The human recall-by-genotype study found greater insulin-secretion reduction and glucose elevation in G-allele carriers. Condition category: normal nutrient_topic: Melatonin research collection; topical membership is not evidence of a direct dietary effect. plain_language: A response can vary with receptor genotype. organism: Human islets and volunteers; separate insulin-cell and mouse experiments tissue_or_cell_type: MTNR1B signaling and insulin secretion experimental_model: Human islet genetics, cell experiments and recall-by-genotype intervention limitations: Genotype associations, cultured-cell manipulation and human intervention are separate evidence types. Do not generalize islet signaling to every tissue. exposure: Risk G allele, receptor overexpression and melatonin exposure evidence_span: {"source_cache": "artifacts/melatonin-research/27185156.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "61fcf7c730c1349e5b306e5c9cfcabcb2905290d7f8762cbfba06f2b5fccaded", "start_char": 0, "end_char": 1043, "text_sha256": "61fcf7c730c1349e5b306e5c9cfcabcb2905290d7f8762cbfba06f2b5fccaded"} [melatonin-p27185156] Increased Melatonin Signaling Is a Risk Factor for Type 2 Diabetes. (2016). https://pubmed.ncbi.nlm.nih.gov/27185156/ DOI: 10.1016/j.cmet.2016.04.009
    Complete structured claim and evidence

  2. MTNR1B overexpression exaggerated melatonin-associated inhibition of insulin release in cells.

    MTNR1B overexpression in experimental insulin-secreting cells → Insulin secretion source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/melatonin-research/27185156.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "61fcf7c730c1349e5b306e5c9cfcabcb2905290d7f8762cbfba06f2b5fccaded", "start_char": 0, "end_char": 1043, "text_sha256": "61fcf7c730c1349e5b306e5c9cfcabcb2905290d7f8762cbfba06f2b5fccaded"}
    experimental_model
    Human islet genetics, cell experiments and recall-by-genotype intervention
    exposure
    Risk G allele, receptor overexpression and melatonin exposure
    limitations
    Genotype associations, cultured-cell manipulation and human intervention are separate evidence types. Do not generalize islet signaling to every tissue.
    nutrient_topic
    Melatonin research collection; topical membership is not evidence of a direct dietary effect. · Melatonin
    organism
    Human islets and volunteers; separate insulin-cell and mouse experiments
    plain_language
    More receptor can strengthen this inhibitory response.
    primary_references
    [melatonin-p27185156] Increased Melatonin Signaling Is a Risk Factor for Type 2 Diabetes. (2016). https://pubmed.ncbi.nlm.nih.gov/27185156/ DOI: 10.1016/j.cmet.2016.04.009
    tissue_or_cell_type
    MTNR1B signaling and insulin secretion

    Melatonin: synthesis, receptors, circadian timing and nutrient interactions (2026-09-17) · lines 1124–1135

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Human islet genetics, cell experiments and recall-by-genotype intervention · source_derived_draft · unverified_draft

    ### melatonin-islet-overexpression MTNR1B overexpression exaggerated melatonin-associated inhibition of insulin release in cells. Condition category: normal nutrient_topic: Melatonin research collection; topical membership is not evidence of a direct dietary effect. plain_language: More receptor can strengthen this inhibitory response. organism: Human islets and volunteers; separate insulin-cell and mouse experiments tissue_or_cell_type: MTNR1B signaling and insulin secretion experimental_model: Human islet genetics, cell experiments and recall-by-genotype intervention limitations: Genotype associations, cultured-cell manipulation and human intervention are separate evidence types. Do not generalize islet signaling to every tissue. exposure: Risk G allele, receptor overexpression and melatonin exposure evidence_span: {"source_cache": "artifacts/melatonin-research/27185156.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "61fcf7c730c1349e5b306e5c9cfcabcb2905290d7f8762cbfba06f2b5fccaded", "start_char": 0, "end_char": 1043, "text_sha256": "61fcf7c730c1349e5b306e5c9cfcabcb2905290d7f8762cbfba06f2b5fccaded"} [melatonin-p27185156] Increased Melatonin Signaling Is a Risk Factor for Type 2 Diabetes. (2016). https://pubmed.ncbi.nlm.nih.gov/27185156/ DOI: 10.1016/j.cmet.2016.04.009
    Complete structured claim and evidence

  3. The morning impairment was attributed primarily to reduced insulin release.

    Melatonin → Insulin secretion source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/melatonin-research/25197811.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "a2ed431f069ffbe6ace434aba258b90c154b1d07e4c6b92816cba26bb3b31c04", "start_char": 0, "end_char": 1466, "text_sha256": "a2ed431f069ffbe6ace434aba258b90c154b1d07e4c6b92816cba26bb3b31c04"}
    experimental_model
    Single-blind placebo-controlled glucose challenges
    exposure
    5 mg melatonin 15 minutes before 75 g OGTT at 09:00 or 21:00
    limitations
    Acute high-exposure challenge; not evidence that every bedtime regimen causes diabetes. Estimated mechanisms varied by time of day.
    nutrient_topic
    Melatonin research collection; topical membership is not evidence of a direct dietary effect. · Melatonin
    organism
    21 healthy young women
    plain_language
    Timing changes which part of glucose regulation appears affected.
    primary_references
    [melatonin-p25197811] Acute melatonin administration in humans impairs glucose tolerance in both the morning and evening. (2014). https://pubmed.ncbi.nlm.nih.gov/25197811/ DOI: 10.5665/sleep.4088
    tissue_or_cell_type
    Oral glucose tolerance in morning and evening

    Melatonin: synthesis, receptors, circadian timing and nutrient interactions (2026-09-17) · lines 1072–1083

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Single-blind placebo-controlled glucose challenges · source_derived_draft · unverified_draft

    ### melatonin-morning-insulin The morning impairment was attributed primarily to reduced insulin release. Condition category: normal nutrient_topic: Melatonin research collection; topical membership is not evidence of a direct dietary effect. plain_language: Timing changes which part of glucose regulation appears affected. organism: 21 healthy young women tissue_or_cell_type: Oral glucose tolerance in morning and evening experimental_model: Single-blind placebo-controlled glucose challenges limitations: Acute high-exposure challenge; not evidence that every bedtime regimen causes diabetes. Estimated mechanisms varied by time of day. exposure: 5 mg melatonin 15 minutes before 75 g OGTT at 09:00 or 21:00 evidence_span: {"source_cache": "artifacts/melatonin-research/25197811.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "a2ed431f069ffbe6ace434aba258b90c154b1d07e4c6b92816cba26bb3b31c04", "start_char": 0, "end_char": 1466, "text_sha256": "a2ed431f069ffbe6ace434aba258b90c154b1d07e4c6b92816cba26bb3b31c04"} [melatonin-p25197811] Acute melatonin administration in humans impairs glucose tolerance in both the morning and evening. (2014). https://pubmed.ncbi.nlm.nih.gov/25197811/ DOI: 10.5665/sleep.4088
    Complete structured claim and evidence

  4. Experimental depletion lowered clamp insulin response by 26% and glucose disposal by 27.4%; estimated tissue insulin sensitivity was unchanged.

    Potassium → Insulin secretion source_derived_draftungraded
    Experimental context and source evidence
    availability_state
    nutrient_deficiency Imported condition classification; unverified.
    cross_nutrient
    Potassium depletion altered carbohydrate handling; the precise cellular link remains unmeasured.
    experimental_contrast
    {"combination": "single", "comparator": "Before depletion in the reported clamp study", "conditions": [{"entity_slug": "potassium", "state": "Experimentally depleted"}], "effect_direction": "decrease", "endpoint": "Clamp insulin response", "intervention": "Experimental potassium depletion"} Comparison extracted from the existing source-pinned Rowe 1980 claim (PMID 6991855); no new primary full-text access in this pass. The raw supports/positive relationship is retained independently.
    experimental_model
    Seven healthy young men; 7-8 days, 40 mEq K/day diet plus 60 g/day sodium polystyrene sulfonate; 2-hour hyperglycemic clamp 125 mg/dL above baseline.
    limitations
    Seven men; diet-plus-resin exposure. No direct beta-cell channel measurement.
    nutrient_topic
    Potassium research collection; topical membership is not evidence of a direct dietary effect. · Potassium
    organism
    Human
    plain_language
    Depletion impaired glucose handling alongside a smaller insulin response.
    primary_references
    [rowe-1980-depletion] Effect of experimental potassium deficiency on glucose and insulin metabolism (1980). https://www.sciencedirect.com/science/article/pii/0026049580900748 DOI: 10.1016/0026-0495(80)90074-8
    tissue_or_cell_type
    Systemic glucose/insulin response
    trigger_kind
    nutrient_deficiency Imported condition classification; unverified.

    Potassium: cross-nutrient mechanisms and deficiency (2026-09-17) · lines 834–844

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Seven healthy young men; 7-8 days, 40 mEq K/day diet plus 60 g/day sodium polystyrene sulfonate; 2-hour hyperglycemic clamp 125 mg/dL above baseline. · source_derived_draft · unverified_draft

    ### k-human-depletion-insulin Experimental depletion lowered clamp insulin response by 26% and glucose disposal by 27.4%; estimated tissue insulin sensitivity was unchanged. Condition category: nutrient_deficiency nutrient_topic: Potassium research collection; topical membership is not evidence of a direct dietary effect. plain_language: Depletion impaired glucose handling alongside a smaller insulin response. organism: Human tissue_or_cell_type: Systemic glucose/insulin response experimental_model: Seven healthy young men; 7-8 days, 40 mEq K/day diet plus 60 g/day sodium polystyrene sulfonate; 2-hour hyperglycemic clamp 125 mg/dL above baseline. limitations: Seven men; diet-plus-resin exposure. No direct beta-cell channel measurement. cross_nutrient: Potassium depletion altered carbohydrate handling; the precise cellular link remains unmeasured. [rowe-1980-depletion] Effect of experimental potassium deficiency on glucose and insulin metabolism (1980). https://www.sciencedirect.com/science/article/pii/0026049580900748 DOI: 10.1016/0026-0495(80)90074-8
    Complete structured claim and evidence

  5. Pancreatic beta-cell Selenot deletion in mice produced an insulin production/secretion deficit and impaired glucose tolerance.

    SELENOT → Insulin secretion source_derived_draftliterature_reviewed:supported_interpretation
    Experimental context and source evidence
    experimental_model
    Human/mouse pancreatic expression and beta-cell-specific Selenot-knockout mice.
    limitations
    Production versus secretion and the direct enzymatic substrate are not fully separated here; the knockout is not a human supplementation trial.
    organism
    Mouse knockout; human and mouse expression

    Selenium: literature corrections and mechanism additions · lines 1097–1106

    Metabolic Ledger literature curation, 17 September 2026; primary papers linked individually · supports · Human/mouse pancreatic expression and beta-cell-specific Selenot-knockout mice. · secondary_verified · secondary_verified

    ## selenot-beta-cell-insulin In the studied mice, pancreatic cells needed SELENOT for normal insulin output. Pancreatic beta-cell Selenot deletion in mice produced an insulin production/secretion deficit and impaired glucose tolerance. Experimental model: Human/mouse pancreatic expression and beta-cell-specific Selenot-knockout mice. Organism: Mouse knockout; human and mouse expression Limitations: Production versus secretion and the direct enzymatic substrate are not fully separated here; the knockout is not a human supplementation trial. Primary reference: [The PACAP-regulated gene selenoprotein T is abundantly expressed in mouse and human beta-cells and its targeted inactivation impairs glucose tolerance](https://pubmed.ncbi.nlm.nih.gov/23913443/)
    Complete structured claim and evidence

Where it participates (unsigned role)

  1. Rat beta-cells release GABA by calcium-dependent exocytosis of synaptic-like microvesicles and the GABA thus released can diffuse over sufficient distances within the islet interstitium to activate GABA-A receptors in neighboring cells, confocal immunocytochemistry revealed the presence of GABA-A receptors in glucagon-secreting alpha-cells but not in beta- and delta-cells with transcripts of alpha1, alpha4 and beta1-3 subunits detected in purified alpha-cells but not in beta-cells, the antagonist SR95531 increased glucagon secretion at 1 millimolar glucose twofold and completely abolished the inhibitory action of 20 millimolar glucose on glucagon release, and basal and glucose-stimulated secretion of insulin and somatostatin were unaffected.

    SR95531, a GABA-A receptor antagonist → Glucagon secretion source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/gaba-research/15047619.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "1f64e75f4c5822ecc05331804e4d127c8b1702249327c4ed85fa07d96898d5b0", "start_char": 0, "end_char": 1478, "text_sha256": "1f64e75f4c5822ecc05331804e4d127c8b1702249327c4ed85fa07d96898d5b0"}
    experimental_model
    Confocal immunocytochemistry, transcript analysis, whole-cell voltage clamp and hormone secretion with a receptor antagonist
    exposure
    Endogenous GABA released from beta cells, with the GABA-A antagonist SR95531 and the calcium channel blocker isradipine
    limitations
    The antagonist experiment is what makes this causal for the endogenous signal. Receptor detection was by immunocytochemistry and transcripts in purified cells.
    nutrient_topic
    GABA research collection; topical membership is not evidence of a direct clinical effect, and the sign of a GABA response depends on the chloride gradient of the cell it was measured in. · Gamma-aminobutyric acid
    organism
    Rat
    plain_language
    Block the receptor and glucose stops switching off glucagon entirely, and the receptor is on the glucagon cell and not on the insulin cell.
    primary_references
    [gb-p15047619] Glucose inhibition of glucagon secretion from rat alpha-cells is mediated by GABA released from neighboring beta-cells. (2004). https://pubmed.ncbi.nlm.nih.gov/15047619/ DOI: 10.2337/diabetes.53.4.1038
    tissue_or_cell_type
    Purified islet cells and intact islets

    GABA: a ligand with no sign of its own, the cofactor that limits its synthesis, the barrier that keeps it out of the brain, and the immune settings where the same molecule protects and harms (2026-09-22) · lines 417–428

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Confocal immunocytochemistry, transcript analysis, whole-cell voltage clamp and hormone secretion with a receptor antagonist · source_derived_draft · unverified_draft

    ### gb-the-receptor-is-on-the-alpha-cell-only Rat beta-cells release GABA by calcium-dependent exocytosis of synaptic-like microvesicles and the GABA thus released can diffuse over sufficient distances within the islet interstitium to activate GABA-A receptors in neighboring cells, confocal immunocytochemistry revealed the presence of GABA-A receptors in glucagon-secreting alpha-cells but not in beta- and delta-cells with transcripts of alpha1, alpha4 and beta1-3 subunits detected in purified alpha-cells but not in beta-cells, the antagonist SR95531 increased glucagon secretion at 1 millimolar glucose twofold and completely abolished the inhibitory action of 20 millimolar glucose on glucagon release, and basal and glucose-stimulated secretion of insulin and somatostatin were unaffected. Condition category: normal nutrient_topic: GABA research collection; topical membership is not evidence of a direct clinical effect, and the sign of a GABA response depends on the chloride gradient of the cell it was measured in. plain_language: Block the receptor and glucose stops switching off glucagon entirely, and the receptor is on the glucagon cell and not on the insulin cell. organism: Rat tissue_or_cell_type: Purified islet cells and intact islets experimental_model: Confocal immunocytochemistry, transcript analysis, whole-cell voltage clamp and hormone secretion with a receptor antagonist limitations: The antagonist experiment is what makes this causal for the endogenous signal. Receptor detection was by immunocytochemistry and transcripts in purified cells. exposure: Endogenous GABA released from beta cells, with the GABA-A antagonist SR95531 and the calcium channel blocker isradipine evidence_span: {"source_cache": "artifacts/gaba-research/15047619.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "1f64e75f4c5822ecc05331804e4d127c8b1702249327c4ed85fa07d96898d5b0", "start_char": 0, "end_char": 1478, "text_sha256": "1f64e75f4c5822ecc05331804e4d127c8b1702249327c4ed85fa07d96898d5b0"} [gb-p15047619] Glucose inhibition of glucagon secretion from rat alpha-cells is mediated by GABA released from neighboring beta-cells. (2004). https://pubmed.ncbi.nlm.nih.gov/15047619/ DOI: 10.2337/diabetes.53.4.1038
    Complete structured claim and evidence

  2. SLC30A8-null and R138X beta cells had fewer crystalline insulin granules; glucose-stimulated secretion was not impaired in the tested system.

    Human stem-cell-derived SLC30A8-null beta cells → Human beta-cell insulin-granule crystallization source_derived_draftungraded
    Experimental context and source evidence
    availability_state
    machinery_impairment Imported condition classification; unverified.
    curation_topic
    zinc · Zinc
    experimental_condition
    Wild-type cells SLC30A8-null or R138X cells · Human stem-cell-derived SLC30A8-null beta cells Condition belongs to the full experimental contrast; do not separate a joint intervention.
    experimental_contrast
    {"intervention": "SLC30A8-null or R138X cells", "comparator": "Wild-type cells", "endpoint": "Granule crystallization", "effect_direction": "decrease", "combination": "single", "conditions": [{"entity_slug": "human-slc30a8-null-beta-cells", "state": "SLC30A8-null or R138X cells"}]} Explicit extracted experimental comparison; source-derived draft.
    experimental_model
    Engineered human embryonic stem-cell-derived beta cells; results and figure 5 reviewed
    limitations
    Separate genotypes, not a combined knockout. Preserved secretion does not establish universal protection.
    primary_references
    SLC30A8 stem-cell study; 2023; PMCID:PMC10047077; https://pmc.ncbi.nlm.nih.gov/articles/PMC10047077/
    trigger_kind
    machinery_impairment Imported condition classification; unverified.

    Diabetes cascade: targeted primary-source supplement · lines 12–12

    See claim-local references; curated paraphrases reviewed 2026-09-20. · supports · Engineered human embryonic stem-cell-derived beta cells; results and figure 5 reviewed · source_derived_draft · unverified_draft

    SLC30A8-null and R138X beta cells had fewer crystalline insulin granules; glucose-stimulated secretion was not impaired in the tested system. Model: Engineered human embryonic stem-cell-derived beta cells; results and figure 5 reviewed. Limits: Separate genotypes, not a combined knockout. Preserved secretion does not establish universal protection. Primary reference: SLC30A8 stem-cell study; 2023; PMCID:PMC10047077; https://pmc.ncbi.nlm.nih.gov/articles/PMC10047077/
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards